checkAd

     109  0 Kommentare Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators

    MONTREAL, June 18, 2024 /PRNewswire/ -- Ability Biologics ("Ability") announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures ("Amplitude"). Amplitude is joined by the Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus and Alexandria Venture Investments. Ability, a pioneer in the application of generative Artificial Intelligence (AI) to therapeutic discovery, focuses its platform on discovering and developing potent and selective antibody therapeutics for cancer and immune-related disorders. Ability Biologics, through its AbiLeap discovery engine, is generating novel, logic-enabled antibodies with the potential to become best-in-class or first-in-class therapeutics.

    Giles Day, Co-Founder and CEO

    Ability's leadership team combines deep experience in immunology, antibody discovery, engineering and therapeutic development, from the bench to commercial stage, and is leveraging this experience to create next generation antibodies using powerful computational tools through its unique, proprietary AI platform. The AbiLeap discovery engine is an AI platform built on top of one of the largest databases of antibody-antigen interactions ever constructed, bringing together more than five years of discovery data and incorporating both public and private data sources. AbiLeap allows Ability to address a longstanding challenge by generating fully human antibodies that are logic-gated, enabling them to target specific tissues and cells based on the local microenvironment, including conditions such as secondary antigens, pH, temperature and/or the presence of specific metabolites.

    "We're seeing a need for a new generation of antibodies and modalities as simply binding, blocking or agonizing a single receptor is not enough to achieve therapeutic impact," said Giles Day, Co-founder and CEO of Ability. "At Ability, our platform overlays multiple approaches in a single molecule, enhancing specificity and selectivity to develop potent therapeutics with broad therapeutic windows. To do so, our antibodies employ tried and tested IgG formats that enable easier manufacturing, storage and administration, avoiding complex formats that introduce multiple risks from manufacturing to immunogenicity," concluded Giles Day.

    Seite 1 von 3




    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Ability Biologics Announces the Closing of its US $18 Million Seed Funding Extension toward the Generation of Novel, Highly Targeted Immunomodulators MONTREAL, June 18, 2024 /PRNewswire/ - Ability Biologics ("Ability") announced the final closing of its seed funding, raising a total of $18 million (US), a financing round led by founding investor Amplitude Ventures ("Amplitude"). Amplitude is …